Patents by Inventor Jong Ik Hwang
Jong Ik Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11739141Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: March 3, 2020Date of Patent: August 29, 2023Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Publication number: 20230104540Abstract: The present disclosure relates to a method of treating a disease or disorder associated with an abnormality in CNS function. Also provided is a method for diagnosing and/or identifying a subject having an abnormality in CNS function. FAM19A1 antagonists that can be used with the present disclosures are also provided.Type: ApplicationFiled: March 2, 2021Publication date: April 6, 2023Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol KIM, Dong Sik KIM, Soon-gu KWON, Nui HA, Jae Young SEONG, Jong Ik HWANG, Hyo Jung YONG, Eun Bee CHO
-
Publication number: 20220372122Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: ApplicationFiled: April 18, 2022Publication date: November 24, 2022Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol KIM, Jae Young SEONG, Jong Ik HWANG, Eun Bee CHO, Junho CHUNG, Junyeong JIN, Tae Young YUNE, Jee Youn LEE
-
Publication number: 20220242910Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.Type: ApplicationFiled: January 19, 2022Publication date: August 4, 2022Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Jae Young SEONG, Jong-Ik HWANG, Dong-Hoon KIM, Gi Hoon SON, Yoo-Na LEE, Seongsik YUN, Arfaxad REYES-ALCARAZ
-
Patent number: 11332521Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: GrantFiled: November 7, 2017Date of Patent: May 17, 2022Assignee: Neuracle Science Co., Ltd.Inventors: Bongcheol Kim, Jae Young Seong, Jong Ik Hwang, Eun Bee Cho, Junho Chung, Junyeong Jin, Tae Young Yune, Jee Youn Lee
-
Patent number: 11248023Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.Type: GrantFiled: July 15, 2019Date of Patent: February 15, 2022Assignee: Neuracle Science Co., LtdInventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
-
Publication number: 20200270337Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: March 3, 2020Publication date: August 27, 2020Applicant: Neuracle Science Co., Ltd.Inventors: Jae Young SEONG, Jong Ik HWANG, Woong SUN, Eun Bee CHO, Won-Ki KIM
-
Patent number: 10640557Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: January 11, 2017Date of Patent: May 5, 2020Assignee: Neuracle Sceince, Inc.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Publication number: 20200010509Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.Type: ApplicationFiled: July 15, 2019Publication date: January 9, 2020Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Jae Young SEONG, Jong-Ik HWANG, Dong-Hoon KIM, Gi Hoon SON, Yoo-Na LEE, Seongsik YUN, Arfaxad REYES-ALCARAZ
-
Publication number: 20190300599Abstract: The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.Type: ApplicationFiled: November 7, 2017Publication date: October 3, 2019Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Bongcheol KIM, Jae Young SEONG, Jong Ik HWANG, Eun Bee CHO, Junho CHUNG, Junyeong JIN, Tae Young YUNE, Jee Youn LEE
-
Patent number: 10385098Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.Type: GrantFiled: November 30, 2016Date of Patent: August 20, 2019Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz
-
Publication number: 20180319841Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.Type: ApplicationFiled: November 30, 2016Publication date: November 8, 2018Applicant: NEURACLE SCIENCE CO., LTD.Inventors: Jae Young SEONG, Jong-Ik HWANG, Dong-Hoon KIM, Gi Hoon SON, Yoo-Na LEE, Seongsik YUN, Arfaxad REYES-ALCARAZ
-
Publication number: 20170121401Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: January 11, 2017Publication date: May 4, 2017Inventors: Jae Young SEONG, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Patent number: 9579398Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: GrantFiled: February 15, 2013Date of Patent: February 28, 2017Assignee: Neuracle Science Co., Ltd.Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-ki Kim
-
Patent number: 9556242Abstract: The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components.Type: GrantFiled: January 20, 2012Date of Patent: January 31, 2017Assignee: ANYGEN CO., LTD.Inventors: Jae-Young Seong, Jong-Ik Hwang, Hyun Kim, Dong-Gyu Kim, Se-Hyung Cho, Gi-Hoon Son, Kyung-Jin Kim
-
Patent number: 9357754Abstract: The present invention relates to a transgenic pig that expresses sTNFR1-Fc, wherein a gene encoding sTNFR1-Fc, which is a fusion protein of the extracellular domain of human soluble tumor necrosis factor receptor (sTNFR1) and an immunoglobulin Fc region, is introduced; a method for preparing the same; an organ isolated from the transgenic pig; a somatic donor cell line inserted with sTNFR1-Fc gene; a method for preparing a blood sample comprising sTNFR1-Fc; and a method for preparing human sTNFR1-Fc from the blood sample of the transgenic pig. As the transgenic pig can suppress immune response and inflammatory response by secreting an inhibitory substance that suppresses the activity of TNF-? in blood, it can be effectively used for xenograft. Furthermore, since the transgenic pig has a blood type O, it can be transplanted for suppressing inflammatory response, regardless of a blood type of recipient.Type: GrantFiled: January 20, 2012Date of Patent: June 7, 2016Assignee: SNU R&DB FOUNDATIONInventors: Curie Ahn, Byeong Chun Lee, Jong Ik Hwang, Jae Seok Yang, Byoung Gon Moon, Goo Jang, Bum Rae Cho, Ok Jae Koo, Sol Ji Park, Jung Taek Kang, Dae Kee Kwon
-
Publication number: 20150118230Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.Type: ApplicationFiled: February 15, 2013Publication date: April 30, 2015Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
-
Patent number: 9018439Abstract: The present invention relates to a method for producing a transgenic pig in which immune rejection response is inhibited, and in which human HO-1 genes and TNFR1-Fe fusion genes are simultaneously expressed. The present invention also relates to a transgenic pig for organ transplantation, which is produced by the method, and in which immune rejection response is inhibited. The present invention also relates to a somatic-cell-donating cell strain for producing the transgenic pig, and to a method for producing organs, from the transgenic pig, in which the immune rejection response is inhibited.Type: GrantFiled: December 21, 2010Date of Patent: April 28, 2015Assignee: Hanwha Advanced Materials CorporationInventors: Curie Ahn, Byeong Chun Lee, Jong Ik Hwang, Jae Seok Yang, Goo Jang, Bum Rae Cho, Ok Jae Koo, Jung Taek Kang, Dae Kee Kwon
-
Publication number: 20140026233Abstract: The present invention relates to a transgenic pig that expresses sTNFR1-Fc, wherein a gene encoding sTNFR1-Fc, which is a fusion protein of the extracellular domain of human soluble tumor necrosis factor receptor (sTNFR1) and an immunoglobulin Fc region, is introduced; a method for preparing the same; an organ isolated from the transgenic pig; a somatic donor cell line inserted with sTNFR1-Fc gene; a method for preparing a blood sample comprising sTNFR1-Fc; and a method for preparing human sTNFR1-Fc from the blood sample of the transgenic pig. As the transgenic pig can suppress immune response and inflammatory response by secreting an inhibitory substance that suppresses the activity of TNF-? in blood, it can be effectively used for xenograft. Furthermore, since the transgenic pig has a blood type O, it can be transplanted for suppressing inflammatory response, regardless of a blood type of recipient.Type: ApplicationFiled: January 20, 2012Publication date: January 23, 2014Applicant: SNU R&DB FOUNDATIONInventors: Curie Ahn, Byeong Chun Lee, Jong Ik Hwang, Jae Seok Yang, Byoung Gon Moon, Goo Jang, Bum Rae Cho, Ok Jae Koo, Sol Ji Park, Jung Taek Kang, Dae Kee Kwon
-
Publication number: 20130345141Abstract: The present invention relates to a composition for regulating circadian rhythms, a composition for diagnosing circadian rhythm disorders and a diagnostic kit, wherein the composition for regulating circadian rhythms comprises NQ peptides, C12orf39 genes, NQ peptides cDNA and the like, which relate to circadian regulation in vertebrates as main components.Type: ApplicationFiled: January 20, 2012Publication date: December 26, 2013Applicant: ANYGEN CO., LTD.Inventors: Jae-Young Seong, Jong-Ik Hwang, Hyun Kim, Dong-Gyu Kim, Se-Hyung Cho, Gi-Hoon Son, Kyung-Jin Kim